JP2020520388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520388A5 JP2020520388A5 JP2020514351A JP2020514351A JP2020520388A5 JP 2020520388 A5 JP2020520388 A5 JP 2020520388A5 JP 2020514351 A JP2020514351 A JP 2020514351A JP 2020514351 A JP2020514351 A JP 2020514351A JP 2020520388 A5 JP2020520388 A5 JP 2020520388A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- thiophene
- formula
- compound according
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 31
- -1 -C (O) -C 1-6 alkyl Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 12
- 229940002612 prodrug Drugs 0.000 claims 12
- 239000000651 prodrug Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 9
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 claims 4
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- NGUUMHKSNSFLOS-UHFFFAOYSA-N 2-methoxyethyl hydrogen carbonate Chemical compound COCCOC(O)=O NGUUMHKSNSFLOS-UHFFFAOYSA-N 0.000 claims 1
- MPHRDYMCSSTOSV-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)sulfanyl-6-(4-morpholin-4-ylphenyl)-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound ClC1=C(C=CC(=C1)Cl)SC1C(NC(CC1=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1)=O MPHRDYMCSSTOSV-UHFFFAOYSA-N 0.000 claims 1
- VIYOREKDGJPDAL-UHFFFAOYSA-N 3-(2-chloro-4-fluorophenyl)sulfanyl-6-(4-morpholin-4-ylphenyl)-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound ClC1=C(C=CC(=C1)F)SC1C(NC(CC1=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1)=O VIYOREKDGJPDAL-UHFFFAOYSA-N 0.000 claims 1
- WZERHEYLHRAQCF-UHFFFAOYSA-N 3-(2-chloro-4-fluorophenyl)sulfanyl-6-(6-ethoxypyridin-2-yl)-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound ClC1=C(C=CC(=C1)F)SC1C(NC(CC1=O)(C1=CSC=C1)C1=NC(=CC=C1)OCC)=O WZERHEYLHRAQCF-UHFFFAOYSA-N 0.000 claims 1
- IKUIRSQFPDRAQK-UHFFFAOYSA-N 3-(2-chloro-4-fluorophenyl)sulfanyl-6-[6-(cyclopentylmethoxy)pyridin-2-yl]-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound ClC1=C(C=CC(=C1)F)SC1C(NC(CC1=O)(C1=CSC=C1)C1=NC(=CC=C1)OCC1CCCC1)=O IKUIRSQFPDRAQK-UHFFFAOYSA-N 0.000 claims 1
- JEIFJFIYSOYMNT-UHFFFAOYSA-N 3-(2-chlorophenyl)sulfanyl-6-(2-morpholin-4-ylpyrimidin-5-yl)-6-thiophen-3-yloxane-2,4-dione Chemical compound ClC1=C(C=CC=C1)SC1C(OC(CC1=O)(C1=CSC=C1)C=1C=NC(=NC=1)N1CCOCC1)=O JEIFJFIYSOYMNT-UHFFFAOYSA-N 0.000 claims 1
- ZTEFMHCAYWPPRS-UHFFFAOYSA-N 3-(2-chlorophenyl)sulfanyl-6-pyridin-2-yl-6-thiophen-3-yloxane-2,4-dione Chemical compound ClC1=C(C=CC=C1)SC1C(OC(CC1=O)(C1=CSC=C1)C1=NC=CC=C1)=O ZTEFMHCAYWPPRS-UHFFFAOYSA-N 0.000 claims 1
- YWRDZRSMNUHCMP-UHFFFAOYSA-N 3-(2-chlorophenyl)sulfanyl-6-pyrimidin-5-yl-6-thiophen-3-yloxane-2,4-dione Chemical compound ClC1=C(C=CC=C1)SC1C(OC(CC1=O)(C1=CSC=C1)C=1C=NC=NC=1)=O YWRDZRSMNUHCMP-UHFFFAOYSA-N 0.000 claims 1
- SLYWPACVUWKZSI-UHFFFAOYSA-N 6-(5-bromopyridin-2-yl)-3-(2-chlorophenyl)sulfanyl-6-thiophen-3-yloxane-2,4-dione Chemical compound BrC=1C=CC(=NC=1)C1(CC(C(C(O1)=O)SC1=C(C=CC=C1)Cl)=O)C1=CSC=C1 SLYWPACVUWKZSI-UHFFFAOYSA-N 0.000 claims 1
- QOZXXUQDVNHSND-UHFFFAOYSA-N 6-(6-bromopyridin-2-yl)-3-(2,3-dichlorophenyl)sulfanyl-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound BrC1=CC=CC(=N1)C1(CC(C(C(N1)=O)SC1=C(C(=CC=C1)Cl)Cl)=O)C1=CSC=C1 QOZXXUQDVNHSND-UHFFFAOYSA-N 0.000 claims 1
- BJIQEKSMSATHGA-UHFFFAOYSA-N 6-(6-bromopyridin-2-yl)-3-(2-chloro-4-fluorophenyl)sulfanyl-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound BrC1=CC=CC(=N1)C1(CC(C(C(N1)=O)SC1=C(C=C(C=C1)F)Cl)=O)C1=CSC=C1 BJIQEKSMSATHGA-UHFFFAOYSA-N 0.000 claims 1
- DKPAMPWXUTVUBC-UHFFFAOYSA-N 6-[6-(cyclopentylmethoxy)pyridin-2-yl]-3-(2,3-dichlorophenyl)sulfanyl-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound C1(CCCC1)COC1=CC=CC(=N1)C1(CC(C(C(N1)=O)SC1=C(C(=CC=C1)Cl)Cl)=O)C1=CSC=C1 DKPAMPWXUTVUBC-UHFFFAOYSA-N 0.000 claims 1
- UTWOFCHGWRXCQP-UHFFFAOYSA-N 6-[6-(cyclopentylmethoxy)pyridin-2-yl]-3-(2,4-dichlorophenyl)sulfanyl-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound C1(CCCC1)COC1=CC=CC(=N1)C1(CC(C(C(N1)=O)SC1=C(C=C(C=C1)Cl)Cl)=O)C1=CSC=C1 UTWOFCHGWRXCQP-UHFFFAOYSA-N 0.000 claims 1
- KQRCMGGAMVEQEA-UHFFFAOYSA-N 6-[6-(cyclopentylmethoxy)pyridin-2-yl]-3-(2,5-dichlorophenyl)sulfanyl-6-thiophen-3-ylpiperidine-2,4-dione Chemical compound C1(CCCC1)COC1=CC=CC(=N1)C1(CC(C(C(N1)=O)SC1=C(C=CC(=C1)Cl)Cl)=O)C1=CSC=C1 KQRCMGGAMVEQEA-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 claims 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- VJKHCRGEYPSWIY-UHFFFAOYSA-N [2-[6-(cyclopentylmethoxy)pyridin-2-yl]-5-(2,4-dichlorophenyl)sulfanyl-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2-methoxyethyl carbonate Chemical compound C(OC=1CC(NC(C=1SC1=C(C=C(C=C1)Cl)Cl)=O)(C1=NC(=CC=C1)OCC1CCCC1)C1=CSC=C1)(OCCOC)=O VJKHCRGEYPSWIY-UHFFFAOYSA-N 0.000 claims 1
- DUNJYSBJTLLFHF-UHFFFAOYSA-N [2-[6-(cyclopentylmethoxy)pyridin-2-yl]-5-(2,5-dichlorophenyl)sulfanyl-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2-methoxyethyl carbonate Chemical compound C(OC=1CC(NC(C=1SC1=C(C=CC(=C1)Cl)Cl)=O)(C1=NC(=CC=C1)OCC1CCCC1)C1=CSC=C1)(OCCOC)=O DUNJYSBJTLLFHF-UHFFFAOYSA-N 0.000 claims 1
- OJXQGCMIURYYMQ-UHFFFAOYSA-N [5-(2,3-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] ethyl carbonate Chemical compound CCOC(=O)OC1=C(SC2=C(Cl)C(Cl)=CC=C2)C(=O)NC(C1)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 OJXQGCMIURYYMQ-UHFFFAOYSA-N 0.000 claims 1
- GDHLLRNOMBGBNG-UHFFFAOYSA-N [5-(2,5-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2,2-dimethylpropanoate Chemical compound C(C(C)(C)C)(=O)OC=1CC(NC(C=1SC1=C(C=CC(=C1)Cl)Cl)=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 GDHLLRNOMBGBNG-UHFFFAOYSA-N 0.000 claims 1
- HCOJBIDYTHVTEU-UHFFFAOYSA-N [5-(2,5-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2-methoxyethyl carbonate Chemical compound C(OC=1CC(NC(C=1SC1=C(C=CC(=C1)Cl)Cl)=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1)(OCCOC)=O HCOJBIDYTHVTEU-UHFFFAOYSA-N 0.000 claims 1
- ZKGUGAMSXJNSPL-UHFFFAOYSA-N [5-(2,5-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2-methylpropyl carbonate Chemical compound CC(C)COC(=O)OC1=C(SC2=C(Cl)C=CC(Cl)=C2)C(=O)NC(C1)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 ZKGUGAMSXJNSPL-UHFFFAOYSA-N 0.000 claims 1
- ITGVGDJCWPGVLQ-UHFFFAOYSA-N [5-(2,5-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] acetate Chemical compound C(C)(=O)OC=1CC(NC(C=1SC1=C(C=CC(=C1)Cl)Cl)=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 ITGVGDJCWPGVLQ-UHFFFAOYSA-N 0.000 claims 1
- JPXCEYXDCUOEII-UHFFFAOYSA-N [5-(2,5-dichlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] pyridine-4-carboxylate Chemical compound C(C1=CC=NC=C1)(=O)OC=1CC(NC(C=1SC1=C(C=CC(=C1)Cl)Cl)=O)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 JPXCEYXDCUOEII-UHFFFAOYSA-N 0.000 claims 1
- BYSREUVARVCUSA-UHFFFAOYSA-N [5-(2-chloro-4-fluorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-4-yl] 2-methoxyethyl carbonate Chemical compound COCCOC(=O)OC1=C(SC2=C(Cl)C=C(F)C=C2)C(=O)NC(C1)(C1=CSC=C1)C1=CC=C(C=C1)N1CCOCC1 BYSREUVARVCUSA-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 0 **=**=C(C(CC(C1Sc2cc(*)c(*)c(*)c2Cl)=O)(c2c[s]cc2)OC1=O)*=* Chemical compound **=**=C(C(CC(C1Sc2cc(*)c(*)c(*)c2Cl)=O)(c2c[s]cc2)OC1=O)*=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1707856.9 | 2017-05-16 | ||
| GBGB1707856.9A GB201707856D0 (en) | 2017-05-16 | 2017-05-16 | Compounds |
| PCT/GB2018/051333 WO2018211277A1 (en) | 2017-05-16 | 2018-05-16 | Ldha activity inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520388A JP2020520388A (ja) | 2020-07-09 |
| JP2020520388A5 true JP2020520388A5 (https=) | 2021-07-26 |
Family
ID=59201440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514351A Pending JP2020520388A (ja) | 2017-05-16 | 2018-05-16 | Ｌｄｈａ活性阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11142520B2 (https=) |
| EP (1) | EP3625225B1 (https=) |
| JP (1) | JP2020520388A (https=) |
| CN (1) | CN110709393A (https=) |
| ES (1) | ES2923652T3 (https=) |
| GB (1) | GB201707856D0 (https=) |
| WO (1) | WO2018211277A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114450399A (zh) * | 2019-05-02 | 2022-05-06 | 卢万天主教大学 | 用于治疗癌症的乳酸脱氢酶抑制剂多肽 |
| WO2023215293A1 (en) | 2022-05-02 | 2023-11-09 | Athanor Biosciences, Inc. | Cancer eradicating – bio-nanoparticles (ce-bnp) |
| WO2025011479A1 (en) * | 2023-07-13 | 2025-01-16 | Meta Pharmaceuticals (Hk) Limited | Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789440A (en) * | 1993-11-19 | 1998-08-04 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| SK283240B6 (sk) | 1993-11-19 | 2003-04-01 | Parke, Davis & Company | 5,6-Dihydropyrónové deriváty ako inhibítory proteázy a protivírusové činidlá a farmaceutická kompozícia obsahujúca tieto deriváty |
| RU2016137674A (ru) * | 2014-03-17 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Производные пиперидиндиона |
| WO2015142903A2 (en) * | 2014-03-17 | 2015-09-24 | Genentech, Inc. | Method of controlling lactate production with piperdine-dione derivatives |
| WO2017055396A1 (en) | 2015-09-30 | 2017-04-06 | Selvita S.A. | Pyrazolidine derivatives and related compounds |
| GB201707852D0 (en) * | 2017-05-16 | 2017-06-28 | Arctic Pharma As | Compounds |
| GB201707846D0 (en) * | 2017-05-16 | 2017-06-28 | Spermatech As | Use |
-
2017
- 2017-05-16 GB GBGB1707856.9A patent/GB201707856D0/en not_active Ceased
-
2018
- 2018-05-16 EP EP18727384.2A patent/EP3625225B1/en active Active
- 2018-05-16 WO PCT/GB2018/051333 patent/WO2018211277A1/en not_active Ceased
- 2018-05-16 ES ES18727384T patent/ES2923652T3/es active Active
- 2018-05-16 US US16/613,837 patent/US11142520B2/en active Active
- 2018-05-16 CN CN201880034909.5A patent/CN110709393A/zh active Pending
- 2018-05-16 JP JP2020514351A patent/JP2020520388A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10519126B2 (en) | Serine/threonine kinase inhibitors | |
| JP5736507B2 (ja) | 含窒素複素環化合物またはその塩 | |
| JP6487925B2 (ja) | セリン／トレオニンキナーゼ阻害剤 | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| US11173145B2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| JP2016513660A5 (https=) | ||
| JP2021504443A5 (https=) | ||
| JP2016514718A5 (https=) | ||
| JP2016512515A5 (https=) | ||
| JP2016527263A5 (https=) | ||
| JP2020505356A5 (https=) | ||
| JP2017532360A5 (https=) | ||
| EA035036B1 (ru) | Производные пиразоло[1,5-а]пиразин-4-ила в качестве ингибиторов янус-киназы (jak) | |
| JP2017537948A5 (https=) | ||
| JP2010513272A5 (https=) | ||
| TW201917126A (zh) | 二氫二酮 | |
| JP2020520388A5 (https=) | ||
| US20250179013A1 (en) | Inhibitors of rna helicase dhx9 and uses thereof | |
| WO2006046734A2 (ja) | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2017536342A5 (https=) | ||
| JP2016508132A5 (https=) | ||
| JP2020531485A5 (https=) | ||
| JP2009537606A5 (https=) | ||
| JP2021523178A5 (https=) |